Hikma Pharmaceuticals PLC (LON:HIK) Insider Sells £49,986 in Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Victoria Hull sold 2,777 shares of the company’s stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of GBX 1,800 ($23.00), for a total value of £49,986 ($63,871.71).

Hikma Pharmaceuticals Trading Up 2.6 %

Shares of LON HIK opened at GBX 1,841 ($23.52) on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The company has a market cap of £5.11 billion, a PE ratio of 18.07, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a 50-day moving average of GBX 2,132.90 and a two-hundred day moving average of GBX 2,014.91. Hikma Pharmaceuticals PLC has a 1-year low of GBX 1,750 ($22.36) and a 1-year high of GBX 2,360 ($30.16).

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, May 1st. Shareholders of record on Thursday, March 20th will be given a $0.48 dividend. This represents a yield of 1.8%. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.32. The ex-dividend date of this dividend is Thursday, March 20th. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 60.84%.

Analyst Ratings Changes

A number of brokerages recently issued reports on HIK. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research report on Friday, March 7th. Berenberg Bank reissued a “buy” rating and issued a GBX 2,560 ($32.71) target price on shares of Hikma Pharmaceuticals in a report on Monday, March 10th.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.